[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Moon (Guangzhou) Biotechnology Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100618465","efficacy-and-safety-of-akkermansia-muciniphila-akm-lab-01-for-overweight-and-obesity-100618465",false,"NCT07331974","Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 for Overweight and Obesity","A Randomized, Double-blind, Placebo-controlled Trial to Access the Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 in Participents With Overweigh and Obesity","Inclusion Criteria:\n\n* 1\\) Age: 18-60 years old (inclusive); Gender: male or female.\n* 2\\) Body Mass Index (24.0≤BMI≤40.0 kg\u002Fm²).\n* 3\\) Has no taken any medications for metabolic control (e.g., for body weight, blood lipids, or blood glucose) within the past month.\n* 4\\) Has been attempting to manage weight primarily through lifestyle interventions (diet and exercise) for at least one month prior to screening.\n* 5\\) Processes adequate communication and cognitive abilities, is expected to be compliant with long-term medication, and has understood the nature, significance, potential benefits, inconveniences, and risks of the study prior to enrollment.\n* 6\\) For participants of childbearing potential (male or female): Must agree to use at least one medically approved form of contraception (e.g., intrauterine device \\[IUD\\], oral contraceptives, or condoms) throughout the trial. For female participants of childbearing potential: Must have a negative serum pregnancy test at screening and must be non-lactating.\n* 7\\) Voluntarily agrees to participate by signing the inform consent form and commits to follow the trial treatment plan and visit schedule.\n\nExclusion Criteria:\n\n* 1\\) A clear history of neurological or psychiatric disorders (including epilepsy and dementia).\n* 2\\) Hyperlipidemia due to secondary causes, such as nephrotic syndrome, hepatic diseases, hypothyroidism, or renal failure.\n* 3\\) Concurrent severe medical conditions deemed by the investigator to require immediate treatment, such as severe diabetes mellitus, hypertriglyceridemia, or cerebrovascular disease.\n* 4\\) Concurrent severe primary diseases of the liver, kidney, or hematopoietic system; or individuals with mental illness.\n* 5\\) Participants with a family history of genetically inherited metabolic disorders.\n* 6\\) Participants currently taking hepatotropic medications.\n* 7\\) Participants with a history of prior bariatric surgery.\n* 8\\) Presence of poorly controlled or unstable acute\u002Fchronic diseases, including but not limited to:\n\n  * Cardiovascular diseases: Unstable angina, myocardial infarction within the past 6 months, symptomatic congestive heart failure (NYHA Class Ⅱ or higher), severe arrhythmia, ect.\n  * Uncontrolled active infectious diseases, malignancies, ect.\n* 9\\) Participants with hepatic or renal insufficiency, defined as:\n\n  * Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \\> 2.5 × ULN (Upper Limit of Normal);\n  * Serum total bilirubin \\> 2.5 × ULN;\n  * Creatinine (Cr) \\> 1.5 × ULN.\n* 10\\) Urine amylase ≥ 1.5 × ULN, or any other laboratory abnormality deemed by the investigator to be clinically significant and incompatible with study participation.\n* 11\\) History of acute diabetic complications (e.g., diabetic ketoacidosis or hyperosmolar hyperglycemic state) within the past 3 months.\n* 12\\) History of gastrointestinal surgery within the past year, or the presence of severe, active gastrointestinal disease that is not stabilized and may affect drug absorption, distribution, metabolism, or excretion.\n* 13\\) Know hypersensitivity or allergy to any active ingredient or excipient of the investigational product.\n* 14\\) Use of antibiotic therapy or intake of probiotics\u002Fprebiotic supplements within 3 month prior to screening.\n* 15\\) Excessive alcohol consumption (defined as \\> 30 grams per day for men or \\> 20 gram, sraems) with the past 10 years.\n* 16\\) pregnant or lactating women.\n* 17\\) Any other medical condition that, in the judgement of the investigator, may put the participant at increased or be aggravated by participation in the study. The specific reason for exclusion based on this criterion must be documented.","ALL","18 Years","60 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is designed as a preliminary investigation to evaluate the weight-loss efficacy and safety of AKM Lab-01 in an overweight or obese population. It is an interventional, radomized, double-blind, placebo-controlled clinical trial. Participants who meet the eligibility criteria will be randomly assigned to receive AKM Lab-01 or a matching placebo. The intervention will be administered once daily for 3 months. Baseline metrics, along with blood, urine, and stool samples, will be collected from participants, before and after the AKM Lab-01 intervention. The analysis will focus on changes in body weight, blood lipids, blood glucose, and gut metagenomic profiles (from stool samples). Furthermore, metabolomic analysis of blood and stool samples will be conducted to explore the potential machanisms through which AMK Lab-01 influences body weight.",[27],"Overweight , Obesity",[29,30,31,32],"Akkermansia Muciniphila","Obesity","Overweight","Probiotics","RECRUITING","2026-06-25",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":21},"2026-07-01",{"date":41,"type":21},"2027-05-31",{"name":43,"class":44},"Moon (Guangzhou) Biotechnology Co., Ltd.","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100618466","efficacy-and-safety-of-probiotics-for-anxiety-depression-100618466","NCT07331987","Efficacy and Safety of Probiotics for Anxiety Depression","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Efficacy and Safety of Probiotics in Participants With Anxiety Depression","Inclusion Criteria:\n\n* 1\\) Age: 18-60 years old; Gender: male or female.\n* 2\\) Meets the diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for a mild-to-moderate depressive or anxiety symptoms.\n* 3\\) Hamilton Depression Rating Scale (HAM-D-24) score ≥ 8 or Hamilton Anxiety Rating Scale (HAM-A-14) score ≥ 7 at screening.\n* 4\\) Has no used of anxiolytic or antidepressant medications (including traditional Chinese patent medicines), with the exception of Escitalopram Oxalate, within 2 weeks prior to the first dose.\n* 5\\) For participants of childbearing potential (male or female): Must agree to use least one medically approve form of contraception (e.g., intrautering device \\[IUD\\], oral contraceptives, or condoms) throughout the trial. For female participants of childbearing potential: Must have a negative urine pregnancy test at screening and must be non-lactating.\n* 6\\) The participant is willing and be able to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* 1\\) HAM-D-24 score ≥ 35 or HAM-A-14 score ≥ 29.\n* 2\\) Presence of significant suicidal ideation.\n* 3\\) History or current diagnosis of neuropsychiatric disorders such as schizophrenia or epilepsy.\n* 4\\) History of head trauma (with loss of consciousness for \\>10 minutes), other unstable major somatic diseases, or any somatic condition that could cause psychiatric symptoms.\n* 5\\) Suspected intellectual disability.\n* 6\\) History of alcohol or substance abuse prior to enrollment.\n* 7\\) Cranial magnetic resonance imaging (MRI) reveals organic lesions.\n* 8\\) Participants who are deemed unsuitable for the study by the investigator for any other reason.",{"count":54,"type":21},60,[24],"This randomized, double-blind, placebo-controlled study will enroll 60 individuals with mild-to-moderate anxiety depression. Following a 3-month intervention and a 1-month follow-up period, the study aims to: 1) evaluate the efficacy of probiotics by comparing anxiety, depression, and sleep scores to baseline; and 2) investigate the safety and underlying mechanisms by analyzing changes in serum biomarkers, gut microbiota, and related metabolites.",[58],"Anxiety Depression",[60,61,62,32],"Depression","Anxiety","Mood",{"date":36,"type":37},{"date":65,"type":37},"2026-06-15",{"date":67,"type":21},"2027-02-28",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":45},"100590964","an-efficacy-and-safety-study-of-akkermansia-muciniphila-akm-lab-01-in-hypercholesterolaemia-100590964","NCT06974266","An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia","A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Preliminary Efficacy of Akkermansia Muciniphila AKM Lab-01 in Subjects With Hypercholesterlemia","AKM Lab-01","Inclusion Criteria:\n\n1. Aged 35-75 years (inclusive), regardless of gender;\n2. Patients diagnosed with hypercholesterolemia (5.2 mmol\u002FL ≤ TC \\\u003C6.2 mmol\u002FL, or 3.4 mmol\u002FL ≤ LDL-C \\\u003C5.0 mmol\u002FL), with or without hypertriglyceridemia (1.7 mmol\u002FL ≤ TG \\\u003C4.5 mmol\u002FL) or mixed hyperlipidemia (defined as: 1.7 mmol\u002FL ≤ TG \\\u003C4.5 mmol\u002FL and 5.2 mmol\u002FL ≤ TC \\\u003C6.2 mmol\u002FL; or 1.7 mmol\u002FL ≤ TG \\\u003C4.5 mmol\u002FL and 3.4 mmol\u002FL ≤ LDL-C \\\u003C5.0 mmol\u002FL; or 1.7 mmol\u002FL ≤ TG \\\u003C4.5 mmol\u002FL, 5.2 mmol\u002FL ≤ TC \\\u003C6.2 mmol\u002FL and 3.4 mmol\u002FL ≤ LDL-C \\\u003C5.0 mmol\u002FL);\n3. Accompanied by overweight\u002Fobesity (24.0 ≤ BMI ≤40.0 kg\u002Fm²);\n4. Have not taken any metabolic control medications (for lipid, weight, or blood glucose) within the past month;\n5. Have controlled of blood lipids solely through lifestyle interventions (diet and exercise) for at least 1 month prior to the screening period;\n6. People must possess communication and cognitive abilities to adhere to long-term medication, and fully understand the nature, significance, potential benefits, inconveniences, and risks of the study before participation;\n7. Fertile patients (male or female) must agree to use at least one medically approved contraceptive method (e.g., intrauterine device \\[IUD\\], oral contraceptives, or condoms) during the trial. Female with childbearing potential must have a negative blood pregnancy test during screening and must not be lactating;\n8. Voluntary enrollment with signed informed consent, and commitment to comply with the trial treatment regimen and visit schedule\n\nExclusion Criteria:\n\n1. Have taken any metabolic control medications (e.g., lipid-lowering, blood glucose-regulating, or weight-loss drugs) within the past month or are currently taking such medications.\n2. Patients with secondary hyperlipidemia caused by conditions such as nephrotic syndrome, liver diseases, hypothyroidism, renal failure, etc..\n3. Have severe comorbidities requiring immediate treatment, including uncontrolled diabetes, hypertriglyceridemia, cerebrovascular diseases, etc., as determined by the investigator.\n4. Have severe primary diseases (e.g., hepatic, renal, or hematopoietic system disorders) or psychiatric conditions.\n5. Patients with a family history of genetically inherited metabolic disorders.\n6. Currently taking liver-affecting medications.\n7. Have a history of bariatric surgery.\n8. People with acute or chronic progressive\u002Funstable diseases deemed unsuitable for enrollment by the investigator.\n9. Hepatic or renal dysfunction: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5×upper limit of normal (ULN); Total bilirubin \\>1.5×ULN; Serum creatinine (Cr) \\>1.5×ULN.\n10. Serum amylase ≥1.5×ULN or other clinically significant laboratory abnormalities per investigator judgment.\n11. Patients with acute diabetic complications (e.g., diabetic ketoacidosis, hyperosmolar hyperglycemic state) within the past 3 months.\n12. Have a history of gastrointestinal surgery within the past year.\n13. People with allergic constitution or hypersensitivity to the investigational product.\n14. Have used antibiotics, probiotics, or prebiotics within 3 months prior to recruitment.\n15. Excessive alcohol consumption in the past decade (\\>30 g\u002Fday for males; \\>20 g\u002Fday for females).\n16. Pregnant or breastfeeding subjects.\n17. Excluded for other reasons as determined by the investigator.","35 Years","75 Years",{"count":54,"type":21},[24],"The purpose of this study was to assess the safety and efficacy of AKM Lab-01 in subjects with hypercholesterolemia. This study will be conducted as a randomized, double-blind, placebo-controlled trial, eligible hypercholesterolemic participants were administered daily oral doses of either AKM Lab-01 or a placebo. Baseline clinical parameters, blood samples, and stool specimens were collected before and after the intervention for comparative analysis.",[83],"Hypercholesterolaemia",{"date":36,"type":37},{"date":86,"type":37},"2025-06-25",{"date":88,"type":21},"2026-12-30",{"name":43,"class":44},""]